Raphael Ceccaldi

To develop innovative molecules with breakthrough therapeutic potential for chemoresistant breast and ovarian cancers.

In 2020, the World Health Organization (WHO) estimated approximately 2.3 million new cases of breast and ovarian cancer worldwide. Within the demanding landscape of oncology research, our innovation stands out as a groundbreaking approach to tackling the complex challenges posed by aggressive breast and ovarian cancers, and notably those related to their resistance to conventional chemotherapy (i.e. platinum and PARP inhibitors) and high mortality rates.

Our project oJers an exceptional opportunity to develop a novel targeted therapy and eJective treatments for chemoresistant tumors. We aim to characterize the physicochemical properties of an innovative class of small molecules targeting a unique therapeutic target identified in our laboratory. The development of such inhibitors could ultimately transform the prognosis for patients with aggressive breast and ovarian Cancers.